Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Podcasts|June 19, 2020
Discovering Psychiatry throughout the 5 Boroughs
Advertisement
Flexibility; creativity. Maryann Popiel, MD, discusses how developments in mental health and an evolving public perception of psychiatry have influenced her practice in an urban community such as the Bronx, and describes career opportunities and a potential career path for psychiatrists in Greater New York City.
Presented by: Maryann J. Popiel, M.D.
Chair, Department of Psychiatry and Behavioral Sciences Department of Psychiatry at Jacobi Medical Center. Dr. Maryann J. Popiel is a psychiatrist for Jacobi and North Central Bronx Hospital with more than 30 years’ experience.
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Spot SVT or POTS masquerading as panic attacks—key heart-rate clues, home maneuvers, and why anxiety can persist even after arrhythmia treatment.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
Phase 1 Data: SNTX-2643 Blunts the Brain's Stress Response After a Single Dose
4
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
5